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Chapter 19
Genetic Modification of Animals: Scientific and 
Ethical Issues
Jarrod Bailey
Senior Research Scientist, Cruelty Free International, United Kingdom 
jarrod.bailey@crueltyfreeinternational.org
1 Introduction
The scientific method demands a willingness to correct and integrate previ-
ous knowledge, based on observable, empirical, measurable evidence and 
subject to laws of reasoning; yet, it has scarcely been applied to non-human 
animal (hereinafter referred to as animal) research. Nevertheless, animal 
use in science started declining in the mid 1970s, at least in the United King-
dom, resulting in a drop in the number of animals used approaching 50% be-
tween the mid-1970s and mid 1980s (UK Home Office, 2016)—perhaps a tacit 
 admission of problematic species differences that render animals poor models 
for  humans. This trend was, however, reversed with the advent of genetically 
modified (GM) animals, animals whose genetic material has been deliberately 
altered in some way by insertion, deletion, or substitution of dna. While the 
decline in use of non-GM animals continued steeply well into the new millen-
nium, overall numbers have been rising for some time, solely due to increased 
utilization of GM animals (Ormandy, Schuppli and Weary, 2009). UK statistics 
for 2015 show that more than two million procedures involved the creation and 
breeding of GM animals, who were not subsequently used in further research 
(around 50% of the total); and there were 720,000 procedures on GM animals 
in further experiments, representing 35% of the total animals used in actual 
experiments (Hendriksen and Spielmann, 2014; UK Home Office, 2016). Trends 
in GM animal use for the rest of the world are difficult to determine due to 
different reporting requirements, but they are likely to be similar, with up to 
50% of the approximately 13 million animals used annually in research in the 
European Union (EU) (Taylor and Rego, 2016), and the estimated 115 million 
animals used globally (Taylor et al., 2008).
This chapter aims to summarize and analyze this shift in the use of animals 
in experiments and, without being overly technical, to ask critically why GM 
Jarrod Bailey - 9789004391192




animals have been so embraced in research. Is this justified? Have they fixed 
problems with species differences and made animal research more human rel-
evant? Are there still issues with species differences, and to what extent? Does 
the new Clustered Regularly Interspaced Short Palindromic Repeats (crispr) 
technique help? Can GM animals ever provide data sufficiently applicable to 
humans? If so, what are the ethical costs? How much pain, suffering, and death 
is involved?
2 What GM Animals Are, How They Are Made, and Problems of 
Efficiency and Specificity
The genome—an organism’s complement of genetic material comprising its 
entire collection of genes and associated elements—comprises long mole-
cules of dna, present in almost all cells. There are many genes along its length, 
each with a defined function(s), and serving as a template(s) for the manufac-
ture of the proteins and enzymes that are the structural and chemical basis 
of life. The genes themselves are made up of subunits, called nucleotides, the 
exact sequence of which determines each gene’s function. The human genome 
contains an estimated 20,000 genes and more than three billion nucleotides. 
Between the genes are other regions of dna that serve, in various ways, to con-
trol the expression of those genes, i.e. when the genes are on or off, or to what 
degree the proteins they produce are synthesized.
Because our genes are fundamental to many normal biological processes, 
they are also at the root of perturbations of these processes that can cause 
things to go wrong, resulting in illness and diseases. Genetic studies have, 
therefore, been pivotal to much biomedical research, attempting to under-
stand the basis of diseases and what can be done to prevent, treat, and cure 
them. Because animal approaches increasingly appear to be of poor human 
relevance, due to the very genetic differences that make species dissimilar and 
unique, some scientists have modified genes in animals used in experiments 
to attempt to overcome these differences and make them more relevant to 
 human biology.
Broadly speaking, genes may be inserted or knocked in to animals, their 
own genes may be deleted or otherwise rendered non-functional or knocked 
out, or existing genes may be modified or repaired to alter their function. 
Creating GM animals has undoubtedly become more efficient and specific 
since their emergence, with the first reports of GM mice in 1974 (Jaenisch 
and Mintz, 1974). Much of what is involved is technical in nature, so it will 
Jarrod Bailey - 9789004391192
Downloaded from Brill.com07/10/2019 04:09:08PM
via free access
445Genetic Modification of Animals
<UN>
not be  discussed in detail here; suffice to say that various methods are avail-
able to introduce the dna of interest—the dna, synthesized in the laboratory, 
which will induce the desired genetic modification—into the zygotes (fertil-
ized eggs) or embryos of the animals to be modified. Briefly, it may be injected 
into fertilized eggs (pronuclear microinjection) or into embryonic stem cells 
(escs or ES cells)—cells in a developing embryo with the capacity to become 
one of many different, specialized types of cell—that are removed from an 
embryo for manipulation and, subsequently, re-injected into developing em-
bryos. These are subsequently surgically implanted into surrogate mothers, in 
which the embryos will develop, as intended, to term and result in live births 
of GM offspring. There are many welfare issues throughout this process, which 
are described later in this chapter. Initially, the technology was crude, with the 
cutting and splicing of dna and insertion of new genes being fairly random 
and with concomitant high wastage of animal lives due to its lack of precision 
and efficiency. While gene editing in escs improved the process, it should be 
noted that, “while it is commonly and frequently claimed that genome editing 
has become significantly (perhaps radically) quicker, cheaper, more efficient, 
easier to use, and therefore more accessible, care is needed when interpret-
ing these claims” (Nuffield Council on Bioethics, 2016, Section 2.6); “progress 
has often been technically challenging […] ES cells have not been obtained for 
most species and, even in mice, where the technology is relatively refined, it is 
time-consuming, expensive, variable, often highly inefficient, and requires a 
special skill set” (Section 1.11 Skarnes, 2015).
One important welfare issue for GM animals, aside from the obvious out-
come of their genetic modification, is the poor efficiency (on-target  efficiency), 
and associated undesired (off-target) effects, of the process. On-target effi-
ciency has increased and off-target effects have decreased significantly with 
the relatively recent discovery of new methods (Hsu, Lander and Zhang, 2014), 
especially the rna-guided programable nuclease gene-editing platform, 
 crispr (crispr/Cas9 system) (see e.g., Chandrasekaran, Song and Ramak-
rishna, 2017). crispr has generated particularly significant excitement, hav-
ing “swept through labs around the world”, at a “breakneck pace [that] leaves 
little time for addressing the ethical and safety concerns such experiments can 
raise.” (Ledford, 2015, pp. 20–21). This is because, in relation to other methods, 
it is less expensive (Ledford, 2015; various components of crispr experiments 
can be bought for as little as US$30), less technically challenging, and less time 
consuming (Caplan et al., 2015). It, therefore, deserves particular attention. 
crispr derives from a bacterial immune system (Fineran and Charpentier, 
2012), and has two components: a single guide rna molecule (sgRNA), which 
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is  specifically designed to seek and bind to precise targets in the genome that 
are to be modified; and an associated enzyme, Cas9, which cuts the dna at the 
target site and initiates the genetic modification process. Put simply, crispr 
causes complete (double-stranded) breaks in the dna at (in theory) specific 
targeted sites, which are subsequently repaired by the cell’s own dna-repair 
systems.
However, the repair process is inherently error prone and generates small 
insertions or deletions of dna at the break sites, which can be used to disrupt 
gene function or, in the presence of engineered dna molecules introduced ex-
perimentally, to alter the dna specifically at that site. While this method is 
generally considered to be much more efficient and specific compared to other 
approaches, any accurate, definitive, quantitative estimation of the efficiency 
of crispr is difficult to find, as estimates vary considerably and are affected by 
many factors, including the nature of the target site and the crispr molecule 
used. Generally, the method has improved over time, but there is a strong argu-
ment that crispr remains far from good enough, scientifically and ethically. 
One 2017 review reported that “knock-in efficiencies are still low and highly 
variable,” with different genetic loci in zebrafish embryos having genes suc-
cessfully knocked in, in 45% and 70% of cases, though only in 1.7% and 3.5% 
respectively, with any real precision. Associated successful germline modifica-
tions to produce founder fish for breeding occurred on average just 3.8% of the 
time (Albadri, Del Bene and Revenu, 2017, p. 8). Another recent study found 
an average of 9.2% of transferred embryos resulted in mouse pups, and an av-
erage of 76% of these had been successfully knocked out for a specific gene. 
The generation of pups harboring specific point mutations was lower: 6.5% 
of transferred embryos produced pups, though less than 8% of these had the 
desired mutation (Nakagawa et al., 2016). In cell lines, mutation efficiencies are 
generally higher, though they range from lower than 5% up to 90%, and gene 
knock in less than 10% up to 66% (see Bortesi et al., 2016).
Regardless of on-target efficiency, one issue has plagued the creation of GM 
animals: off-target effects, or mutations induced by the GM process that are 
not intended but affect other non-specific sites in the genome (Fu et al., 2013; 
Hsu et al., 2013; Pattanayak et al., 2013). This is a significant scientific and wel-
fare issue, which raises serious concerns over the wider application of genetic 
modification in science, medicine, and agriculture (Kanchiswamy et al., 2016; 
Kleinstiver et al., 2016). These concerns include: the low birth rates of animals 
with the desired genetic modification and the associated high “wastage”, or 
animals that may suffer and/or be killed as a result; and many animals who 
harbor off-target mutations adversely affecting the animal’s characteristics 
(phenotype) (Guha, Wai and Hausner, 2017). Significant off-target dna  cleavage 
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and mutation results in toxicity to those cells in which it occurs (Kim et al., 
2009), and their repair causes chromosomal rearrangements, which can acti-
vate genes that can cause cancer (Cradick et al., 2013; see also Cho et al., 2014). 
Not surprisingly, “major concerns of off-target mutations have been observed 
in medical and clinical studies,” as well (Kanchiswamy et al., 2016, p. 564). This 
leads to difficulty in interpreting data but may also cause these animals further 
pain and suffering, due to the off-target effects, and death as they succumb to 
adverse off-target effects or are killed because they are of no experimental use.
Despite the considerable effort put into improving the situation, the ex-
tent of off-target effects is still a matter of serious debate (Bassett, 2017). 
Astoundingly, they are thought to be up to 50% more common than the 
desired on-target mutation efficiency, and they may occur at sites quite differ-
ent to the target site, both of which are of serious concern (Fu et al., 2013; see 
also Bortesi et al., 2016; Komor, Badran and Liu, 2017). Many computational 
approaches to assessing potential crispr off-target problems exist. Though 
useful, each is biased regarding the type of off-target sites it may or may not 
fail to predict. It is therefore widely accepted that other, unbiased methods 
of assessment must be used to help avoid missing off-target effects that may 
be seen experimentally (see Bolukbasi, Gupta and Wolfe, 2016; D’Agostino and 
D’Aniello, 2017; Tsai et al., 2015). Some crispr experiments show more than 100 
off-target mutations, while others appear to show none (Bolukbasi et al., 2016). 
Some  analyses have suggested little or no off-target activity for some crispr 
molecules, though these analyses examined preselected genomic sites only 
so are likely to suffer from bias (see Bortesi et al., 2016). Any single technique 
will miss off- target sites that others will detect; and, unfortunately, the most 
comprehensive method—whole genome sequencing—is technically difficult 
and expensive. For example, a rare mutation (0.1% frequency) would require 
sequencing 1,500 genomes to give a 95% probability of finding this mutation at 
least once (Sluch et al., 2015).
A recent (2017) study attempted to complete a comprehensive whole-genome 
analysis to determine the actual prevalence of all off-target mutations in a 
crispr-edited mouse, not only the larger mutations, such as insertions and 
deletions (indels) of dna but also the smaller, though no less important, single 
nucleotide variants (snvs) that are often not sought. Schaefer and colleagues, 
reported “an unexpectedly high number of snvs,” in addition to an average of 
146 indels, with many of these in known genes (Schaefer et al., 2017, p. 547). 
The authors concluded that “concerns persist” over the unpredictable nature 
of crispr off-target mutation sites, which were likely to have a detrimental 
impact on key cellular processes and would likely manifest in adverse phe-
notypes. This specific issue remains, however, highly controversial. In March 
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2018, Schaefer and colleagues retracted their paper—in the face of pressure 
from some members of the scientific community working on crispr—on the 
grounds that the study results were irreproducible and unsupported by the 
data, and the study lacked key controls (Editorial, 2018; Schaefer et al., 2018). 
Retraction of this paper does not, of course, remotely prove or even suggest 
that crispr is sufficiently free of off-target effects to be safely used in humans. 
Most stakeholders who have opined in its wake have urged further progressive, 
yet cautious, research to elucidate the situation and stopped short of inferring 
an all clear from the authors’ most recent work (Schaefer et al., 2018). With 
particular regard to their revision, Schaefer et al. are careful to note (correctly) 
that their latest data suggest that, “in specific cases, crispr […] may not intro-
duce numerous, off-target mutations” (Abstract). Others note that this  simply 
means that the concern over off-target effects “just isn’t perhaps as big as that 
initial study suggested.” (Brown, 2018). More generally, all involved appear 
to accept that far too little data exist to reach any robust, definitive conclu-
sions about off-target effects associated with crispr, either way. This sensible, 
evidence-based view is supported by the many studies that exist, with a full 
spectrum of results (such as those referenced in this chapter), that serve only 
to rubber stamp the view that this field is young, and the question of off-target 
effects is still completely wide open.
Crucially, just before this Volume went to press, this caution was further jus-
tified by a detailed study published in Nature Biotechnology, which showed 
that the specificity of crispr-induced genetic alternations had been over- 
estimated to date, due to exploration of them being “limited to the immediate 
vicinity of the target site and distal off-target sequences” (Kosicki et al., 2018). 
The authors’ more thorough and detailed investigations revealed that—in two 
different types of mouse cells and a differentiated  human cell-line alike—mu-
tagenesis at the target sites was often much more significant than intended/
expected. Instead of the aforementioned small insertions or deletions of dna, 
the resulting crispr-mediated genetic alterations were frequently “large dele-
tions and more complex genomic rearrangements”, often extending to many 
kilobases. Further, off-target lesions often resulted in “genomic damage”, which 
“may have pathogenic consequences.” The important warnings of their con-
clusions bear repeating here: extensive on-target genomic damage is a com-
mon outcome; consequences are not limited to the target locus but will affect 
more distal genes; some repercussions may initiate neoplasia (cancer); it is 
likely that some cells in each protocol would contain important pathogenic 
lesions, some of which would become cancer-causing in time; and others. 
Such frequent and extensive genetic damage is and has been undetectable 
by  the  means often used to identify it, leading to its under-reporting and 
under-appreciation, and so much more comprehensive analysis of the genetic 
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consequences of crispr experiments is warranted and necessary. This may be 
of urgent concern due to the fact that six clinical trials of crispr are currently 
underway, for various malignancies/cancers, including esophageal, nasopha-
ryngeal, gastric, non-small cell lung cancer, leukemias/lymphomas and other 
hematological malignancies (see Clinicaltrials.gov).
Clearly, off-target mutations remain a major issue, with persistent targeting 
of unintended genomic loci (Bisaria, Jarmoskaite and Herschlag, 2017, p. 21; see 
also Tsai and Joung, 2016), even as steps are taken to mitigate their occurrence 
and effects, such as using engineered/modified crispr components (see e.g. 
Bayat et al., 2017; Chandrasekaran, Song and Ramakrishna, 2017; Combes and 
Balls, 2014; Ding et al., 2016; Guha, Wai and Hausner, 2017). It is widely believed 
that the factors controlling crispr’s precision and accuracy “are still not ful-
ly understood,” and obstacles remain on the path to any clinical application 
(Jiang and Doudna, 2017, p. 524). “Much remains to be learned regarding the 
efficiency and specificity of crispr/Cas9-mediated gene editing in human 
cells, especially in embryos.” (Liang et al., 2015, p. 364) It is considered “nec-
essary” to develop methods of detecting off-target mutations that are much 
more sensitive (Tsai and Joung, 2016, p. 310); but it is also thought that these 
will never be removed completely (Bassett, 2017), and that off-target effects 
will still occur often, no matter how high the on-target specificity (Liang et 
al., 2015). Off-target mutations remain stubbornly numerous and confounding 
in spite of many, multi-faceted efforts to reduce them and their impact; and 
this may have  serious consequences for the use of crispr, even in laboratory-
based  research, where there will be more acceptance of them. This means that 
the role of off-target effects in any observations cannot be ruled out, but espe-
cially in clinical settings, where safety is paramount and even off-target muta-
tion frequencies as low as 0.1% can have serious consequences (Tsai and Joung, 
2016).
Finally, shortly before this Volume went to press, yet another, but differ-
ent, clarion call for great caution came in the form of two papers published 
in Nature (Ihry et al., 2018; Haapaniemi et al., 2018). The double-strand dna 
breaks created by crispr/Cas9 as part of its mechanism of action activate a 
gene called p53, which is known as the “guardian of the genome”—involved 
in the repair of dna damage and, if that damage is sufficiently significant, in 
apoptosis, or the destruction of the cell containing the damaged dna. It is 
because of these functions that p53—a tumor suppressor gene—is known to 
be mutated in more than half of all human cancers (Hollstein et al., 1991; Fo-
ronda and Dow, 2018); if p53 cannot carry out its normal activities, damaged 
cells may go on to become tumorous (Ferrarelli, 2018). This is an issue because, 
as one might expect, p53 blocks crispr/Cas9 activity; and it therefore follows 
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that cells that are experimentally modified by crispr, must, thus, tolerate 
dna damage, and so must have deficient p53. In selecting for crispr-modified 
cells, therefore, one may be selecting for cells that could lead to tumor forma-
tion, which could be clinically catastrophic. As one of the authors opined, “By 
picking cells that have successfully repaired the damaged gene we intended to 
fix, we might inadvertently also pick cells without functional p53. If transplant-
ed into a patient, as in gene therapy for inherited diseases, such cells could give 
rise to cancer, raising concerns for the safety of crispr-based gene therapies.” 
(Karolinska Institutet, 2018).
It has been suggested that such cells could be identified and eliminated by 
in vitro screening (Foronda and Dow, 2018), but various problems remain. Just 
one, single dna break seems to be sufficient to prime p53 activity, and lead to 
cell arrest or death (Foronda and Dow, 2018; Ihry et al., 2018), so the problem 
may be greater than first thought. Some have inferred or implied that this is a 
new discovery, but it is not: almost quarter of a century ago, this was demon-
strated in human fibroblasts (Di Leonardo et al., 1994). Further, crispr-editing 
issues were reported in 2016 with some types of cells, including primary and 
stem cells (Hockemeyer and Jaenisch, 2016; Carroll, 2018), the latter being the 
type of cell involved in one of the recent Nature papers (Ihry et al., 2018)—so 
this may be another illustration of lack of caution among some crispr re-
searchers and advocates, and further reason to doubt that due caution and 
critical approach are being applied widely enough—particularly as the under-
lying mechanism was not pursued (Carroll, 2018). As stated in a recent, highly 
relevant review, “It is surprising that this phenomenon was not recognized 
much earlier.” (Carroll, 2018). Because break-induced toxicity has not been de-
tected in all cell types, but also due to it not being seen in some cell types that 
do have functional p53, it means that “the induced arrest phenomenon will 
have to be tested and addressed for each type of target cell” as “that pathway is 
not the whole story” (Carroll, 2018). Finally, while selection is possible in vitro, 
it is not an option for in vivo somatic gene correction, in which this would have 
serious consequences for animals and humans (Foronda and Dow, 2018).
3 Current and Intended Uses of GM Animals
3.1 Biomedical
Many GM animals are used in basic research with no direct application (for 
example, to a particular therapy for a specific disease), but with aims to investi-
gate the functions of particular genes, for example, and the nature of their reg-
ulation. Others are used as specific models for many different human diseases, 
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including multiple infectious diseases, such as hiv, immune system defects, 
blood and metabolic disorders, muscular dystrophy, cancer immunotherapies, 
among others (Cornu, Mussolino and Cathomen, 2017). Gene therapy inter-
ventions for some of these diseases have already reached clinical trials, such as 
hiv/aids therapies (Cornu, Mussolino and Cathomen, 2017); though there are 
some serious concerns over potential immune reactions in humans to two of 
the most common proteins used in the crispr/Cas9 system. Recent analysis 
of human blood samples revealed the presence of antibodies to Cas9 proteins 
in 65%–79% of individuals; and around half of all the blood samples harbored 
immune cells with the potential to destroy human cells, containing one of the 
Cas9 proteins (Charlesworth et al., 2018). The potential severity of any immune 
reaction in patients is unknown, but it could range from making crispr non-
functional, to dangerous inflammatory reactions.
Efforts are being made to use crispr to deactivate and render some 
viruses non-infectious and/or non-pathogenic, such as hepatitis B and C  viruses 
and hiv (Doerflinger et al., 2017; Huang et al., 2017; Li et al., 2017; Moyo et al., 
2017; Soppe and Lebbink, 2017). Serious caution has been advised, however, 
due to the risk of causing mutations that increase, rather than decrease, viru-
lence (Wang et al., 2016). It is claimed that crispr holds the key to translating 
data from rodent models of psychiatric disorders and neurobehavioral traits 
to humans, including disorders associated with anxiety, mood, and substance 
and impulse-control (Baud and Flint, 2017, p. 373). crispr’s potential for can-
cer biology has been expounded, as it can recreate potential cancer-causing 
 mutations identified in human tumors, in both cell lines and GM animals 
(Guernet and Grumolato, 2017). Some GM animals are used in attempts to pro-
duce medically important proteins, for example, in cows’ milk, which can be 
generated in high volumes and purified from the milk for clinical use. Examples 
include treatments for some blood disorders, osteoporosis, and emphysema 
(Moura, Melo and de Figueiredo Freitas, 2011). GM animals are central to 
 efforts to use animals as a source of organs for human transplantation (xeno-
transplantation), targeting biological pathways involved in immune rejection 
of transplanted organs.
3.2 Farm/Food Animals
A major application of GM technology (GM also can mean genetic modification 
or manipulation, as well as genetically modified) is the engineering of animals 
used for food (Ledford, 2015). Examples include, chickens producing only fe-
male offspring for egg-laying, cows producing only male offspring for better 
meat yield, pigs who can be fattened with less food, cashmere goats producing 
more meat from greater muscle mass and longer hair for greater wool yield; 
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and efforts to facilitate greater stocking density, such as cattle without horns 
and animals with greater resistance to disease (see Frewer et al., 2013; Nuffield 
Council on Bioethics, 2016). Double-muscled pigs (Cyranoski, 2015), rabbits (Lv 
et al., 2016), sheep and cows (Proudfoot et al., 2015; Luo et al., 2014) have been 
created for human consumption, though many died early and were unhealthy, 
and birthing difficulties occurred due to their size (Cyranoski, 2015). Cows with-
out horns can be housed more densely with lower risk of goring injuries (Loria 
K, 2016; Carlson et al., 2016). While there may be welfare benefits— millions 
of cattle would no longer need to be dehorned, which can be very painful—
they would be farmed more intensively and have less space to live in, further 
compromising their welfare. Other efforts include cows that produce milk that 
does not induce allergies in humans (Yu et al., 2011); milk with altered fatty acid 
content, and milk that contains high levels of lactoferrin (Yang et al., 2008a); 
cows who produce “tastier beef” because their flesh contains more fat (Guo 
et al., 2017); and pigs who bleed out more efficiently at slaughter (Hai et al., 2014) 
and have omega-3 fatty acids in their flesh (Lai et al., 2006). GM salmon, modi-
fied so that they grow at twice the rate of normal salmon and can be housed 
in tanks on land, have been approved for human consumption in the United 
States (US) (Connor, 2015). Much of this is undoubtedly the result of lobbying 
by vested interests that stand to profit from these projects, who assert that, for 
instance, the Earth’s growing population and shifting appetites will necessitate 
considerable increases in food production that cannot be achieved by any  other 
means alone; yet, there is strong counter evidence and opinion that alterna-
tive strategies could meet that need, such as reducing food wastage; changing 
consumer demand and preferences for meat, dairy, and eggs; and improving 
farming and production methods by other means (High Level Panel of Experts 
on Food Security and Nutrition, 2014). Despite the potential for both direct and 
indirect effects on animal welfare in this area, it is  acknowledged that too little 
attention has been devoted to the genetic modification of “farm animals” and 
to the regulation of the practice (Nuffield Council on Bioethics, 2016).
However, the creation of GM animals commonly used for food is not lim-
ited to making them easier to manage or more profitable for their meat and 
milk. Pigs are touted as being more appropriate models of human diseases 
than mice, for example, for cystic fibrosis, cancer, diabetes, neurological disor-
ders, high cholesterol, and muscular dystrophy; while a gene associated with 
achondroplasia has been targeted in cattle (Carlson et al., 2012; Petersen and 
Niemann, 2015).
3.3 Dogs and Monkeys
Concerns that less strict regulations in countries outside of the EU and the 
US may lead to GM projects that may not be approved elsewhere appear to 
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have substance. Prior to crispr, a Chinese group created transgenic dogs who 
emitted red fluorescent light (Hong et al., 2009). This was far from efficient. 344 
embryos transferred to 20 surrogate mother dogs, resulted in seven pregnan-
cies and six live births. More recently, another Chinese laboratory created GM 
dogs using crispr, knocking out a gene controlling muscle growth, resulting 
in dogs who were “much more muscular” (Doane, 2016; Zou et al., 2015). Their 
work was defended via a tenuous link to the creation of future dogs who could 
model, for example, Parkinson’s disease; but only two of 60 edited embryos 
were “successful.” Elsewhere in China, GM monkeys have been created with 
apparently similar characteristics to autism. Eight macaques (out of “dozens” 
of GM embryos) were born with a gene (MECP2) linked to autism in humans, 
who showed signs such as running “obsessively in circles”, ignoring their peers, 
and grunting anxiously when stared at (Cyranoski, 2016b; Liu et al., 2016; Snow-
don, 2016).
Interestingly, when espousing the use of “large animals” as GM models for 
human diseases, those who may otherwise stoutly defend GM mice are open to 
criticizing them. For example, one recent paper, authored by scientists  creating 
GM livestock, noted that “the drawbacks of using rodents to model humans 
are well established […] mice make poor models for reproductive physiology, 
pulmonary problems, metabolic regulation, and many other fields of inquiry” 
(West and Gill, 2016). Unfortunately for such advocates, as discussed in this 
chapter and in works referenced in it, it appears that “larger animals”, GM or 
not, remain poor models for these areas and more, and can only ever be so. 
This is compounded by the same, or even greater, confounding issues of low 
efficiency and a variety of limitations and complications (see section on non-
human primates, nhps, below).
4 Suffering, Welfare, and Ethical Issues with GM Animals
Many animal researchers acknowledge that creating GM animals involves suf-
fering at every step, from generating sufficient eggs to embryos for  modification, 
through to the pain and suffering experienced by many progeny (Laboratory 
Animal Science Association, 2008; Robinson, Jennings and Working, 2004).
4.1 Breeding and the GM Process
Producing eggs for the embryos used in the GM process involves drug-induced 
superovulation of females, whose fertilized eggs are collected post-mating, 
which may involve killing the females, a common practice in rodents, or at 
least surgery under general anesthesia (more “valuable” species). Approved 
killing methods for rodents are, commonly, neck dislocation or carbon dioxide 
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suffocation, which can both (not surprisingly) cause distress (Robinson et al., 
2004). Both superovulation and fertilized-egg collection can cause discom-
fort, stress, and post-operative pain (Camara, et al., 2008). After modification, 
embryos are implanted into surrogate mothers in the form of pseudopregnant 
females, who have been previously mated with vasectomized males (The Boyd 
Group, 1999). Pre- and post-natal death of offspring may be significant. One 
report showed that an average of just 29% of implanted embryos survived to 
weaning, and only a quarter of these (7% of implanted embryos) (Hubrecht, 
1995), or an average of 15% ( Robinson et al., 2004), may be GM. Miscarriages 
may cause pain and distress, and such poor efficiency means that many donor 
and recipient animals must be used to produce a relatively small number of 
desired GM individuals. Genotyping of resultant offspring may involve blood 
sampling or tissue biopsy. Invasive methods are still common, including tail 
snipping, ear snipping/punching, or even toe amputation, all causing pain 
in mice (Robinson et al., 2004). The genetic modification process has been 
documented, at least in larger animals, such as sheep and cattle, as a factor 
in  increased gestation length, greater body weight, risk of dystocia (difficult 
birth), and various perinatal anomalies and loss. In mice, there is also evidence 
of increased embryonic and fetal loss (Camar et al., 2008).
4.2 Animal Lives Wasted
The persistent inefficiency of the GM process is a serious welfare issue (Boyd 
Group, 1999; Camara et al., 2008; Laboratory Animal Science Association, 2008; 
Robinson et al., 2004). It is difficult to quantify, as many countries do not re-
quire the reporting of GM-animal statistics (Taylor et al., 2008). In the UK, sta-
tistics indicate a high degree of wastage (around 50% of a total of more than 4 
million animal procedures in 2015, involved the creation and breeding of GM 
animals not used in subsequent experiments), and specific GM license appli-
cations are revealing: seven projects from 2014–2015 proposed using a total of 
almost 27,000 animals ( UK Home Office, 2014).
4.3 Effects of Genetic Modification
Inserted genetic material may have adverse effects on GM embryos/animals. 
Some may be unpredictable, such the aforementioned off-target effects; while 
others are expected and the result of on-target effects, such as GM mice who 
will develop painful cancers. Naturally, the GM process may not necessarily 
adversely impact welfare; but the critical point is that, frequently, the welfare 
consequences of the GM process cannot be predicted in detail, nor can they 
be assessed properly. Welfare assessments are by their nature wide open to 
subjectivity and opinion, and much more research needs to be done in this 
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area to increase objectivity, if indeed this is possible to any significant degree 
(Hawkins et al., 2011, Wells et al., 2006). Therefore, it is acknowledged that 
 reduced viability or impaired health may be expected (Bundesamt für Veter-
inärwesen, 2006); while some estimates suggest around 20% of GM animals 
suffer minor discomfort, 15% severe discomfort, and 30% increases in mortality 
and susceptibility to disease (Thon et al., 2002).
Indications may include, for instance, developmental abnormalities, such as 
cleft palate; perinatal and post-weaning mortality; skeletal abnormalities, in-
cluding malformed limbs; discharge from eyes and ears; diarrhea; poor posture, 
gait, and ataxia; stereotypies, such as lack of alertness, poor or over- grooming, 
circling in cage; absence of teeth; poor mothering; poor  thermoregulatory 
ability; enhanced growth of tumors and development of metastases, often at 
atypical sites; increased aggression; seizures; a range of diseases,  including dia-
betes, osteoporosis, degenerative joint disease, inflammatory bowel disease, 
and ulcerative colitis; sensory and locomotor abnormalities affecting sight, 
hearing, smell, balance, and social interactions; and increased incidence of 
infectious disease (Dennis, 2002). GM mice databases reveal progressive hear-
ing loss and deafness; development of diabetes; impaired movement and 
coordination, including tremors and involuntary movements, difficulty in ini-
tiating movement, abnormal posture, and paralysis; susceptibility to infectious 
disease; colitis; progressive muscle weakness; kidney inflammation; premature 
death; intestinal obstruction; respiratory distress; hyperactivity; heart failure; 
internal bleeding/brain hemorrhage; self-harm; seizures; vision problems and 
blindness; and many more (e.g., Mouse encode Consortium, mouseencode.
org; Mouse Genome Informatics, mgi, database, informatics.jax.org). The 
Mouse Genome Informatics (mgi) database lists mice under the following cat-
egories (among others): with abnormality of blood, connective tissue, head or 
neck, limbs, metabolism, prenatal development/birth, cardiovascular system, 
digestive system, ear, eye, genitourinary system, immune system, musculature, 
nervous system, respiratory system, skeletal system, and cancers. The scale 
of this must also be mentioned: as of July 2017, the mgi database cites 51,000 
 mutant alleles in mice, with more than 3,100 human disease models; the Inter-
national Mouse Strain Resource (findmice.org) lists around 40,000 strains as 
available worldwide; the International Knockout Mouse Consortium has gen-
erated around 5,000 mutant mouse lines (Rosen, Schick and Wurst, 2015); and 
the International Mouse Phenotyping Consortium intends to generate 20,000 
knockout mouse strains (mousephenotype.org) (Koscielny et al., 2014).
Off-target modifications may induce mutations that abrogate gene  function 
and/or cause rearrangements of the genome with other, subsequent muta-
tional effects on other genes. In assessing effects of GM on welfare, it has been 
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cautioned that setting a “normal” baseline must be done carefully. For example, 
it is normal for GM mice engineered to have vestibular abnormalities to spend 
much time circling in their cages. This may be normal for these mice but should 
not be considered normal from a welfare perspective (Hawkins et al., 2011).
4.4 Increasing Numbers of GM Animals
Many of these welfare issues are not exclusive to crispr and exist for other 
GM methods. It has been argued that crispr should mitigate many of these, 
with its simplicity and greater efficiency, and so should be welcomed by ani-
mal advocates. To some extent this may be true, in time. However, the corol-
lary gives great cause for concern, that this simplicity and efficiency will also 
“not only increase in the range and diversity of transgenic rodent strains but 
will greatly expedite transgenesis in other species, including non-human pri-
mates” (Combes and Balls, 2014, p. 137). In this regard, crispr is described as a 
mixed blessing (Hendriksen and Spielmann, 2014); and animal ethicist Bernard 
Rollin (2015) accepts that easier GM techniques would undoubtedly lead to an 
 increase in the number of animals used “as more researchers engage in hither-
to impossible animal research”. It has been said that crispr will  revolutionize 
mouse genetics by reducing the time it takes to create a new GM model from 
years to months, or even weeks (Fellmann et al., 2017). In other words, for any 
reduction and refinement in any specific GM experiment due to crispr, a 
greater overall number of GM experiments will offset this, compounded by 
more experiments on a wider range of species, including dogs and monkeys.
This is not mere speculation. Aside from being logical, and in addition to 
multi-stakeholder enthusiasm for crispr and associated market projections, 
it is clear from current scientific literature. Many speculative claims for crispr 
reflect an excitement that, in part, is responsible for the great expansion of 
interest in the technology and in the creation of greater numbers of GM ani-
mals in academe, biotech firms, and large pharmaceutical companies (Cor-
nu et al., 2017). For example, it is estimated that by 2021, the GM market will 
be worth US$6.28 billion (MarketsandMarkets, 2017). It has, therefore, been 
strongly suggested that the welfare consequences of genetic modification 
for all  species should be monitored and explored in greater detail. Perhaps, 
at least, an in-depth, systematic, critical assessment of the rationale for using 
GM animals in human disease research is warranted; and projects involving GM 
animals  should be approved only in “extremely exceptional circumstances” 
(Combes and Balls, 2014, p. 143; see also Mepham et al., 1998). Unfortunately, 
interest in crispr is, at least for now, manifesting in substantial animal use. 
The scientific literature shows (as of June 2017) more than 6,000 publications, 
up from fewer than 4,000 just a year earlier (June 2016), and just over 600, 18 
months prior to that (Nuffield Council on Bioethics, 2016).
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4.5 Increasing Numbers of Non-Human Primates (nhps)
There is, therefore, great, well-founded, concern that this interest will trans-
late into greater creation of GM monkeys (e.g. Liu et al., 2014; Niu et al., 2014). 
Examples of GM primates have already been mentioned (Cyranoski, 2016b; 
Liu et al., 2016; Sasaki et al., 2009; Snowdon, 2016), following on from, for ex-
ample, the first reports of GM macaques in 2001 (Chan et al., 2001), and a GM 
nhp model of Huntington’s disease (Yang et al., 2008b). Some scientists are 
calling for further increases. To illustrate, a 2016 paper lamenting the failure 
of animal research (including nhps) to translate to a greater understanding 
of human brain disorders and their treatment—largely due to “lack of good 
animal models” and “profound differences in brain and behavior” between 
humans and nonhumans—puts its weight firmly, and speculatively, behind 
GM nhps as a solution (Jennings et al., 2016, p. 1123). Associated suffering is 
justified by a brief assurance of veterinary oversight and intervention. While 
accepting that greatly expanding GM nhp creation and use is challenging in 
many ways, the authors propose a “concerted international effort” to over-
come those  challenges (Jennings et al., 2016, p. 1128), involving automated 
methods for training the animals to comply with the researchers’ demands, 
chronic use of intracranial electrodes, and the creation of an international 
network of nhp centers and vendors. Overall, a horrifying vision for animal 
advocates, and scientifically unjustifiable in any case. My colleagues (at Cru-
elty Free International, and indeed in the wider animal protection commu-
nity) and I agree that there is a “dismal record of drug development for neuro-
logical and psychiatric disease over the past several decades” and that “basic 
neuroscience has failed to deliver substantially new and effective treatments 
for many brain disorders, partially because the animal modelling was done in 
species whose brains are too dissimilar from those of humans” (Jennings et al., 
2016, p. 1128). However, we believe that modifying a gene or two in these poor 
models cannot overcome these problems or lead to research that is any less 
unethical.
GM nhp creation also suffers from the same problems as GM rodents, even 
16 years after the first GM monkey was born (Chan et al., 2001); and so, wide-
spread, efficient, successful, generation of human-relevant GM nhps may be 
a forlorn hope anyway (Luo, Li and Su, 2016). Surprisingly little analysis had 
been done of this until recently. Though crispr has intensified the genera-
tion of GM nhps, targeting efficiency in nhps is still low, “successful gene 
replacement in monkeys via the cripsr/Cas9 system remains elusive, possibly 
due to the complexity of dna repair mechanisms in monkeys” (Luo et al., 2016, 
p. 242), and “there are still some technical limitations for its use in non-human 
primates” (Guo and Li, 2015). A 2017 report acknowledges “the incidence of 
undesirable outcomes has not been well characterized”. It states: “Most studies 
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experienced very high rates of developmental arrest (can be 90%) … [which] 
further raises concerns about non-genetic technical factors contributing to low 
rates of survival” (Midic et al., 2017, p. 4). While this study claimed that the cre-
ation of GM nhp embryos could be 80%-100% efficient, this does not reflect on 
the efficiency of generating otherwise healthy adult nhps with desired  genetic 
modifications, and without confounding and/or welfare- compromising off- 
target effects. The same study suggests that  mosaicism (where offspring con-
tain cells with different genes/gene variants) is “substantial” and is “a significant 
limitation,” and accepts that the creation of GM nhps to date was “achieved at 
a very high cost in terms of the number of embryos used,” due in part to the 
“very limited (around 10%) viability of transferred embryos to term” (Midic 
et al., 2017, p. 15; see also Chen et al., 2015). They conclude that inefficiency 
remains “a major barrier to practical use of the technology in nonhuman pri-
mates” (Midic et al., 2017, p. 15); and that the entire process is financially costly. 
To illustrate, one effort to generate GM nhps via crispr, with two disrupted 
genes, reported that of 22 embryos injected, 15 (68%) survived culturing, while 
on average just over one third of these contained the desired modification (Niu 
et al., 2014). Subsequent attempts to generate GM monkeys involved injecting 
186 zygotes; 83 (45%) were transferred to 29 surrogate females, establishing 10 
pregnancies (34%), with 19 fetuses. The paper was published while 8/10 were 
still pregnant; one miscarried, and the other gave birth to twins, whose genes 
had been successfully modified, though mosaicism was confirmed, and pheno-
type had yet to be established.
This is all of particular concern because experimentation on monkeys is 
opposed much more strongly than on rodents (Aldhous, Coghlan and Copley, 
1999; Animal Aid, 2003; Clemence and Leaman, 2016; Leaman, Latter and Clem-
ence, 2014; tns Opinion & Social, 2010); and genetic manipulation of “higher” 
organisms evokes stronger concern from the public (Olsson and Sandøe, 2010). 
The European Science Foundation’s European Medical Research Councils 
group has stated: “Whether a species needs special protection should not be 
based solely on its phylogenetic relations to humans, but on its potential for 
suffering. nhps are distinguished by the very advanced nature of their social, 
cognitive, sensory, and motor functions” (Olsson and Sandøe, 2010, p. 185).
5 Failure of GM Animals and Consequences for Animals  
and Humans
Much has been published on the failures of GM animals to live up to their prom-
ise, though criticisms of GM animals are frequently understated, couched, for 
example, as follows: they do not always accurately reflect the human condition; 
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they have limitations; data must be interpreted carefully; and so on. Examples of 
failures are numerous, and include Parkinson’s and Alzheimer’s diseases, cystic 
fibrosis, type i and type ii diabetes, amyotrophic lateral sclerosis, Kallmann’s 
syndrome, Lesch-Nyhan’s disease, ataxia-telangiectasia, sickle-cell anemia, 
deafness, visual defects, Duchenne muscular dystrophy, Down’s syndrome, and 
schizophrenia (Pratt et al., 2012), multiple sclerosis, cancers, and immunothera-
py (Ruggeri, Camp and Miknyoczki, 2014), migraine (Storer, Supronsinchai and 
Srikiatkhachorn, 2015), pain (Craig, 2009; Mogil, 2009), and depression (Benatar, 
2007; Bhogal and Combes, 2006; Davis, 2008; McGonigle, 2014; Norgren, 2004; 
Webb, 2014). It is, however, increasingly acknowledged in scientific literature 
that GM animals are failing to deliver by any measure. For example, GM-based 
“advances” in animal models of many human conditions and diseases “have not 
made a significant increase in improving the rate of success in Phase ii proof-
of-concept studies”; in other words, GM animals are not leading to more, bet-
ter, safer drugs and indeed may well be hindering the process because they are 
misleading (Hunter, 2011, p. 1). GM-animal models of cns disorders “have been 
increasingly criticized in the wake of numerous clinical trial failures of nces 
[new chemical entities, or new drugs] with promising preclinical profiles” 
(McGonigle, 2014, p. 140), and they are “criticized for their limited ability to pre-
dict nce efficacy, safety and toxicity in humans” (McGonigle and Ruggeri, 2014, 
p. 162). Clinical trials of gene therapy for heart failure and muscular dystrophy, 
despite early promise, have failed (Hulot, Ishikawa and Hajjar, 2016; Lu, Cirak 
and Partridge, 2014). And despite many years of substantial effort in the field of 
xenotransplantation, and early promises that successful transplantation of pig 
organs into humans would be realized by 2010 and worth multiple billions of 
dollars, the most recent developments claim no more success than a GM pig’s 
heart surviving in a monkey for 51 days (Johnston, 2016), or in the abdomen of 
a baboon in addition to its own heart for just over two years, until they were re-
jected when immunosuppressive drugs were reduced (Mohiuddin et al., 2016; 
Servick, 2016).
Attempts to overcome other significant hurdles continue, such as porcine 
endogenous retrovirus (perv) in pigs, which can cause problems in humans 
(Yang et al., 2015); but there remain persistent issues, such as immune rejec-
tion; transmission of infectious agents; ethical problems and boundaries; as-
pects of physiological compatibility, such as discrepancies in coagulation and 
metabolism; and others (Niemann and Petersen, 2016). Some argue xenotrans-
plantation is not needed anyway. Prevention of much of the need for trans-
plantation via education and health measures, improved donor recruitment, 
and mandated choice and presumed consent/opt-out schemes, and others 
have all had positive outcomes in countries that have adopted them (Perera, 
Mirza and Elias, 2009).
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With specific regard to crispr, there is also evidence to question claims 
that it can improve matters and facilitate more accurate and human-relevant 
models. An approach utilizing Morpholino oligomers (MOs) has been widely 
used to investigate gene function in zebrafish, but attempts to confirm findings 
for specific genes using crispr have been extremely confounding. One study 
reported that most genes altered by crispr failed to show similar phenotypes 
to experiments that altered the expression of the same genes using MOs, which 
the authors attributed to differing off-target effects from the techniques (Kok 
et al., 2015). This is mirrored in a study comparing selected genes affected by 
crispr and a gene-silencing method using short hairpin rnas (shRNA). These 
methods were found to have similar precision; but each affected “numerous” 
genes that the other did not, attributable to differences in off-target effects 
and in the timing of each (Morgens et al., 2016). To illustrate, a recent study 
revealed that previous research implicating the melk gene in certain breast 
cancers—with sufficient certainty to prompt pharmaceutical companies to 
develop drugs to block its activity, some of which proceeded to human trials—
may be unreliable. When the melk gene was knocked out using crispr, can-
cer cells multiplied unexpectedly, and drugs that targeted melk still stopped 
their growth. This casts doubt on the role of melk, and suggests that drugs 
targeting melk work through other targets (Lin et al., 2017).
It is often, perfectly reasonably, asked if such failures may be balanced 
against any successes of GM technology. This is not the purpose of this chapter, 
which is to highlight issues and caveats with it and to supply a more critical ar-
gument against its use. However, any claimed successes, in which it is implied 
that the use of GM animals has resulted directly in human benefit, must fulfil 
the following criteria: data from the GM animal experiments must be reliably 
and sufficiently translatable to humans; these experiments must have provid-
ed data that could not have been obtained in any other way; and these data 
must have been critical to the ultimate human benefit. Even if, for the sake 
of argument, one assumes such examples exist, they still must be balanced 
against an objective appraisal of the scale of failure and against the ethical cost 
of the animal research involved.
6 Reasons for These Failures
Reasons proffered for this scale of failure include the evolutionary distance 
of humans and non-human species—approximately 65 million years for 
 humans and mice—and all consequent differences in gene complement 
and  expression, the artificiality of induced diseases, and the inbred strains of 
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 animals often used (Davis, 2008). See also two comprehensive reviews of ge-
netic differences between humans and chimpanzees (chimpanzees were used 
in science in the US until very recently), and humans and monkeys (Bailey, 
2011, 2014). Even with current knowledge, limited because such differences 
have barely been sought, they are much more widespread and extensive, with 
significant and varied consequences, than is generally accepted. There are sig-
nificant differences in gene complement, but more importantly, in gene ex-
pression, i.e., how these genes are regulated and used in the organism, even 
where they are common to both species. These differences affect all biologi-
cal systems, but notably the immune system, the brain, and the liver, which 
are fundamental to much biomedical research involving infectious agents and 
disease, autoimmunity and inflammation, neuroscience and neurological dis-
eases, and drug safety and efficacy. It is these differences that underpin the 
failures of animal research, whether GM or not, discussed in this chapter.
Of course, genetic differences between humans and nhps, as appreciable as 
they are, are not as great as those between humans and mice, who constitute 
the greatest numbers of GM animals used in science. These differences have 
not yet been elucidated in detail, but illustrative examples exist. For example, 
a systematic comparison of the mouse and human genomes has revealed that 
there is significant conservation of functional genes themselves, with around 
half of human dna aligning with mouse dna when directly compared; how-
ever, this of course means that half of it does not. Furthermore, there are, 
crucially, “wide ranging differences” in many biological pathways and cellular 
functions, which show “considerable divergence”; and the areas of the genome 
that control and regulate gene expression are substantially different (Yue et al., 
2014, p. 355). Indeed, many disease-causing mutations are in these areas, rather 
than in the main protein-coding parts of genes themselves. Because these dif-
fer, particularly between species, this can make direct animal-human compari-
sons not just difficult and uncertain, but impossible (Bassett, 2017). Even when 
humans and mice share genes, they can show functional differences: a study 
of 120 genes that are known to be essential for life in humans, revealed that 
almost one quarter of them are not essential for life in mice (Liao and Zhang, 
2008).
The problem with a shift toward GM nhps, in the hope of greater human 
relevance, is that there is little or no evidence to support this, even if nhps 
are evolutionarily less removed from humans. While it is true to some extent 
that nhps “are genetically and phenotypically closer to humans, particularly in 
regards to anatomy, physiology, cognition, and gene sequences,” it does not fol-
low that they are, therefore, “optimal animal models for genetic modification 
in an attempt to understand human biology” (Luo et al., 2016, p. 241,). This is 
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only valid if this results in better translation of nhp data to human benefit. 
I argue that it does not, because there is simply no evidence that it does.
One positive for animal advocates, while reading myriad literature on the 
burgeoning creation of GM animals, is that there now appears to be more hon-
esty about, and criticism of, the human relevance of non-GM animals. A paper 
in the prestigious journal, Nature, cited the wholesale failure of new drugs to 
treat amyotrophic lateral sclerosis (als), a fatal neurodegenerative condition, 
known as Lou Gehrig’s or motor neuron disease, despite success in animal 
models of the disease, as well as similar failures in Alzheimer’s and cancer, 
among others (Perrin, 2014). Contemporary criticisms of animal research are 
welcome because they have been scant from the scientific community for 
 decades. Ironically, many criticisms are akin to those made by animal  advocates 
for many years, which were roundly dismissed. What seems commonplace, 
however, is the unfortunate and groundless assertion that genetic modifica-
tion will instantly make failed animal models more human relevant. Evidence 
suggests otherwise.
7 Alternatives to GM Animals—The Way Forward
If not GM animals, what is the way forward to understand the myriad human 
diseases and realize treatments and cures for them? Modeling human diseases 
in cultured human stem cells continues to take great leaps forward and will 
surely become a mainstay of biomedical research that “could rival the use of GM 
mice in popularity” (Musunuru, 2013. p. 901). Somatic cells (cells from various 
parts of the body, other than reproductive cells, such as sperm and eggs, often 
skin biopsies or blood) can now be reprogrammed to act as cells in  early-stage 
embryos, able to develop into many different specialized cell types (Takahashi 
et al., 2007; Takahashi and Yamanaka, 2006). Immense collaborative efforts 
now collect and characterize cells from many thousands of healthy and dis-
eased human individuals, many with a wide variety of disorders, and use these 
induced pluripotent stem cells (iPSCs) for comparative studies of normal and 
diseased states and screening of potential new drugs and therapies, including 
the study of polygenic disorders (diseases involving many genes). The develop-
ment of 3D cell cultures and organoids (cultured miniature  organs) is likely to 
increase the in vivo relevance of this approach, with more faithful and accurate 
cellular phenotypes (see Bassett, 2017). Organoids successfully developed to 
date include, brain, intestine, stomach, salivary gland, esophagus, pancreas, 
liver, breast, lung, prostate, fallopian tube, and taste bud (see Driehuis and Cle-
vers, 2017). Genetically modifying such iPSCs and  organoids adds another level 
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of sophistication, allowing potential causative gene variants or mutations to 
be introduced for further study, for example, to validate mutations implicated 
in causing disease and/or for attempts at repairing faulty genes.
Cell lines for these studies have been generated for many diseases, includ-
ing Parkinson’s, Alzheimer’s, Huntington disease, various immune disorders, 
cardiomyopathy, and cystic fibrosis (Brookhouser et al., 2017; Nishizaki and 
Boyle, 2017); and efforts at repairing mutated genes in these systems have been 
promising in, for example, cystic fibrosis and cancers (Driehuis and Clevers, 
2017), and retinopathies (Quinn, Pellissier and Wijnholds, 2017). The combined 
use of genome editing and iPSCs offers the ability to study genes and muta-
tions in different human genetic backgrounds, which is especially important 
for the study of complex neurological disorders. This approach has been found 
to “closely mimic cellular and molecular features of human diseases.” (Heiden-
reich and Zhang, 2016, p. 42) crispr has also aided the derivation of retinal 
ganglion cells from human pscs, to model human optic nerves in vitro for re-
search into optic nerve disease (Sluch et al., 2015). The very high efficiency of 
these types of methods, coupled with the relative ease and speed of the pro-
cess, and the ability to use and screen many thousands of cell lines in parallel, 
means that this type of approach to understanding the basis of human disease 
and to identify therapeutic targets and therapies must be the way forward, in 
place of creating GM animals (see Bassett, 2017). While the aforementioned 
off-target effects are a confounding factor, they matter much less in cell lines 
than in animals, because there are no ethical problems; and cell lines can be 
produced, screened, and evaluated much more quickly and efficiently.
8 Summary
Acknowledgement of the suffering of GM animals has, at least, led to some 
efforts to reduce it, even if these have not, to date, led to overall reductions 
in their creation and experimental use. Guidelines for the use and care of 
GM animals, for example, are welcome. Working Groups and international 
guidelines have been commissioned to this end (Wells et al., 2006) and are at 
least intended to reduce the number of GM animals created and improve the 
welfare of those who are. These include requiring attempts to establish the 
appropriateness of generating any GM animal, both scientifically and with re-
gard to welfare, involving a harm-benefit analysis; and a stipulation that new 
animals should not be generated if similar suitable lines already exist, and/
or if an in vitro method could be used instead (Rose et al., 2013). These guide-
lines need to be widely adopted and enforced, but also greater training of staff 
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responsible for care, for example, can only make little or no impact on the 
welfare of the many millions of GM animals that will end up in laboratories 
worldwide. Ultimately, guidelines or not, GM animals suffer greatly, in their 
tens of millions each year. Controversially, one developing effort to address 
this, already attempted in rats, is to make GM animals who—while still able 
to sense pain—are incapable of finding its sensation unpleasant (Shriver, 
2015).
Yet, the public demands that such pain and suffering is avoided or con-
trolled at all costs for them to accept animal research, GM or not (Aldhous et 
al., 1999; Animal Aid, 2003; Clemence and Leaman, 2016; Leaman, Latter and 
Clemence, 2014; tns Opinion & Social, 2010). Generally, people are much less 
accepting of GM animals than they are of GM plants and GM food compared to 
other GM applications. While perceptions of risk are offset by perceived ben-
efits (Frewer et al., 2013), there is evidence that the EU populace has in the past 
“morally rejected genetic engineering of animal models of disease,” which is 
incompatible with the direction in which worldwide attitudes and laws are 
moving (Rollin, 2015, p. 114). Utilitarians may argue that human benefit out-
weighs this pain and suffering. But, given the degree of animal pain and suffer-
ing involved, both qualitatively and quantitatively, the relatively small number 
of people who stand to benefit from any breakthrough for many of the rare 
genetic diseases that may be modelled, and how unlikely GM animals are to 
contribute to breakthroughs given the burgeoning evidence against them, how 
can this be so? This is especially true if any harm-benefit analyses applied to 
license applications for animal experimentation are conducted properly and 
more stringently, as there are calls for authorities to ensure (Würbel, 2017).
Even if one presumes sufficient human benefit from research on GM ani-
mals, which I (and many others) believe is not supported by evidence, there 
remain serious scientific issues with, and ethical/welfare consequences of, 
genetic engineering. Despite the best currently available method of crispr 
having “swept through labs around the world” recently, and being touted as a 
“revolution” (Ledford, 2015, pp. 20–21), it is still considered as being “in an im-
mature phase of development” and “not yet ready for therapeutic applications 
in humans given the low editing efficiency” (<15%) (D’Agostino and D’Aniello, 
2017, p. 4). This is also due to the persistent concerns over the stubborn na-
ture of off-target mutations, occurring at frequencies of up to 60%, more than 
the best efficiency of intended on-target modifications. Even if off-target is-
sues can be greatly reduced, which is questionable, they are still of concern 
clinically, as “Even low-frequency events could potentially be dangerous if they 
 accelerate a cell’s growth and lead to cancer” (Ledford, 2015, p. 22).
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The efficiency of crispr translation to clinical applications is also of con-
cern. Scientists using crispr to correct a disease-causing mutation in mice in 
a gene therapy experiment had to “pump large volumes of liquid into blood 
vessels—something that is not generally considered feasible in people” and 
this corrected the mutation in just 0.4% of the mice’s cells, not enough to be 
effective (Ledford, 2015, p. 21). Delivery methods for introducing the crispr 
apparatus to cells also need optimizing (Peng, Lin and Li, 2016). Carrier dna 
used to introduce crispr to target cells may become integrated into the host 
genome, causing off-target effects, which may disrupt the genome editing pro-
cess and can cause toxicity. Alternative methods may be stressful to cells, alter-
ing gene expression, or leading to high off-target effects (Peng, Lin and Li, 2016). 
Despite these concerns, the first clinical trial involving crispr commenced in 
October 2016, when knockout immune cells were injected into patients as po-
tential therapy for metastatic non-small cell lung cancer (Cyranoski, 2016a); 
and now crispr is already part of ten clinical trials just a few years after it 
became mainstream (clinicaltrials.gov). It remains to be seen if they will be 
successful, and if so, how much they rely on GM animal research.
9 Conclusion
GM animal creation and experimentation takes the lives of tens of millions of 
animals each year and involves considerable suffering at every stage. Its sci-
entific value is extremely poor, to the point of it being unnecessary, mislead-
ing and therefore harmful not just to the animals involved, but also to people, 
who depend on good science to understand, treat, and cure the diseases that 
affect us all. The continued insistence of many who practice and fund GM re-
search that animals must be used is without foundation. Non-human animals 
have always been bad models for humans due to species differences, and no 
amount of genetic modification can remedy that, even if it were perfect. GM 
processes are far from perfect, however. Even the best is extremely inefficient, 
and confounded not just by those species differences, but also by off-target 
effects of the GM process. These issues are at the root of animal research fail-
ing to be relevant and reliable for humans, of animals being poor models for 
disease right across the spectrum, and of the failure of 90%-95% of new drugs 
in human trials that were successful in animal tests (Bailey, Thew and Balls, 
2013; Bailey, Thew and Balls, 2014; Bailey, Thew and Balls, 2015). Moving away 
from animal research, including the use of GM animals, has never been more 
imperative.
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